Dyne Therapeutics, Inc.

NasdaqGS:DYN 주식 보고서

시가총액: US$3.4b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Dyne Therapeutics 미래 성장

Future 기준 확인 2/6

Dyne Therapeutics (는) 각각 연간 19.8% 및 60.4% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 29.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -126.9% 로 예상됩니다.

주요 정보

19.8%

수익 성장률

29.5%

EPS 성장률

Biotechs 수익 성장24.1%
매출 성장률60.4%
향후 자기자본 수익률-126.9%
애널리스트 커버리지

Good

마지막 업데이트17 Jun 2024

최근 미래 성장 업데이트

Recent updates

Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials

May 21

We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

May 04
We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Dyne: H2 2024 Muscle Disease Data Could Boost Value

Mar 05

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Dec 05
We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

Aug 09
Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Mar 26
We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dec 10
We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Aug 26
Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate

Jul 12

Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251

Jul 05

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 05
Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Jan 12
We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth

Sep 29
We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth

Dyne Therapeutics' chief scientific officer Romesh Subramanian steps down

Jun 02

Here's Why We're Not Too Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 12
Here's Why We're Not Too Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

Dyne Therapeutics EPS beats by $0.10

May 06

Could The Dyne Therapeutics, Inc. (NASDAQ:DYN) Ownership Structure Tell Us Something Useful?

Jan 27
Could The Dyne Therapeutics, Inc. (NASDAQ:DYN) Ownership Structure Tell Us Something Useful?

Dyne Therapeutics posts encouraging data from its pre-clinical myotonic dystrophy trial

Jan 11

Beneficiary Dyne Therapeutics rises on competitor Sarepta's miss in DMD trial

Jan 08

수익 및 매출 성장 예측

NasdaqGS:DYN - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/202658-276-216-3066
12/31/202515-294-237-2679
12/31/2024N/A-256-236-2109
3/31/2024N/A-257-220-220N/A
12/31/2023N/A-236-189-188N/A
9/30/2023N/A-208-184-182N/A
6/30/2023N/A-189-176-175N/A
3/31/2023N/A-177-152-150N/A
12/31/2022N/A-168-157-154N/A
9/30/2022N/A-181-157-153N/A
6/30/2022N/A-182-141-137N/A
3/31/2022N/A-160-157-152N/A
12/31/2021N/A-149-123-120N/A
9/30/2021N/A-126-114-112N/A
6/30/2021N/A-97-98-96N/A
3/31/2021N/A-77-59-58N/A
12/31/2020N/A-59-48-47N/A
9/30/2020N/A-36-32-30N/A
6/30/2020N/A-28-23-22N/A
3/31/2020N/A-21-18-17N/A
12/31/2019N/A-15-13-12N/A

애널리스트 미래 성장 예측

수입 대 저축률: DYN 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: DYN 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: DYN 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: DYN 의 수익(연간 60.4% ) US 시장( 8.7% 보다 빠르게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: DYN 의 수익(연간 60.4% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: DYN (는) 3년 내에 수익성이 없을 것으로 예상됩니다.


성장 기업 발견